CME Background Information

Release, Review, and Expiration Dates

The 2012 NCDEU Poster Session was published in June 2012 and is eligible for AMA PRA Category 1 Credit™ through December 31, 2012. The latest review of this material was May 2012.

To obtain credit for this activity, study the material and complete the CME Posttest and Evaluation.

Objective

After completing this educational activity, you should be able to:

Statement of Need and Purpose

This special 2012 NCDEU Poster Session was developed based on our assessment of the needs of participants in CME activities provided by the CME Institute of Physicians Postgraduate Press, Inc., who have requested information on current research relevant to clinical practice.

Accreditation Statement

The CME Institute of Physicians Postgraduate Press, Inc., is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

The CME Institute of Physicians Postgraduate Press, Inc., designates this educational activity for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Financial Disclosure

The presenters for this CME activity and the CME Institute staff were asked to complete a statement regarding all relevant personal financial relationships between themselves and their spouse/partner and any commercial interest. The CME Institute has resolved any conflicts of interest that were identified. No member of the CME Institute staff reported any relevant personal financial relationships. Financial disclosures from the presenters are as follows:

Dr Baker is an employee of Otsuka.

Ms Bansal is an employee of Medical Decision Modeling.

Mr Furiak is an employee of Medical Decision Modeling; is a consultant for Eli Lilly, Abbott, Endo, and Boehringer-Ingelheim; and has received grant/research support from NIM-SBIR (NIMH).

Mr Ghan is an employee of Medical Decision Modeling.

Dr Gilmer is a consultant for Pfizer and AstraZeneca, has received grant/research support from Forest and NeoSync, and has received honoraria from and is a member of the speakers/advisory board for Neuronetics.

Mr Greenberg is an employee of Analysis Group and is a consultant for Otsuka.

Mr Huang is an employee of Analysis Group and is a consultant for Otsuka.

Dr Iosifescu is a consultant for CNS Response.

Dr Kirson is an employee of Analysis Group and is a consultant for Otsuka.

Dr Lin is a consultant for Otsuka.

Dr Mirski is an employee of Otsuka.

Dr Nierenberg has served as a consultant to the APA, Appliance Computing/Mindsite, Basliea, Brain Cells, Brandeis University, Bristol-Myers Squibb, Dey, Dainippon Sumitomo, Eli Lilly, EpiQ, Mylan, Novartis, PGx Health, Shire, Schering-Plough, Takeda, and Targacept; has consulted through the MGH Clinical Trials Network and Institute for AstraZeneca, Brain Cells, Dainippon Sumitomo, Sepracor, Johnson & Johnson, Labopharm, Merck, Methylation Science, Novartis, PGx Health, Shire, Schering-Plough, Targacept, Takeda, and Lundbeck; has received grant/research support from MGH via NIMH and AHRQ, Forest, Pamlab, Pfizer, and Shire; has received honoraria from Belvior Publishing, University of Texas Southwestern Medical Center, Hillside Hospital, American Drug Utilization Review, ASCP, Baystate Medical Center, Columbia University, CRICO, Dartmouth Medical School, IMEDEX, Israel Society for Biological Psychiatry, Johns Hopkins University, MJ Consulting, New York State, MedScape, MBL Publishing, National Association of Continuing Education, Physicians Postgraduate Press, SUNY Buffalo, University of Wisconsin, University of Pisa, University of Michigan, University of Miami, APSARD, ISBD, SciMed, Slack Publishing, and Wolters Klower Publishing; has been a member of the advisory boards for Appliance Computing, Brain Cells, Eli Lilly, Johnson & Johnson, Takeda, Lundbeck, Targacept, and InfoMedic; owns stock options in Appliance Computing and Brain Cells; and, through MGH, holds copyrights for the Clinical Positive Affect Scale and the MGH Structured Clinical Interview for the Montgomery Asberg Depression Scale and has a patent extension application for the combination of buspirone, bupropion, and melatonin for the treatment of depression.

Dr Offord is an employee of Otsuka.

Mr Samuelson is a consultant for Analysis Group.

Mr Smolen is an employee of Medical Decision Modeling and received grant/research support from NIH.

Dr Wong is a consultant for Otsuka.

Mr Yermakov is an employee of Analysis Group and is a consultant for Otsuka.

Drs Deckersbach, Fan, Gonenc, Moore, Randolph and Rapaport have no personal affiliations or financial relationships with any commercial interest to disclose relative to this presentation.

Disclosure of Off-Label Usage

In this 2012 NCDEU Poster Session, participants may be presenting investigational information about pharmaceutical agents that is outside US Food and Drug Administration–approved labeling. This information is intended solely as continuing medical education and is not intended to promote off-label use of any of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.

Review Process

This 2012 NCDEU Poster Session has been reviewed for accuracy and fair balance by a selection committee of the American Society of Clinical Psychopharmacology (ASCP).

Acknowledgment

This 2012 NCDEU Poster Session is derived from the 52nd Annual NCDEU Meeting, which was held May 29–June 1, 2012, in Phoenix, Arizona, and was independently developed by the CME Institute of Physicians Postgraduate Press, Inc., the National Institute of Mental Health (NIMH), and the ASCP. The opinions expressed herein are those of the presenters and do not necessarily reflect the opinions of the CME provider and publisher, the NIMH, or the ASCP.